NCT06799559View on ClinicalTrials.gov

Study on the Efficacy and Safety of QLM1016 in Schizophrenia

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

402

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2026

Conditions
Schizophrenia
Interventions
DRUG

3-6mg QLM1016

3-6mg QLM1016 pluse Aripiprazole dummy oral solution film administered orally once daily for 6 weeks

DRUG

10-20 mg Aripiprazole oral solution film

10-20mg Aripiprazole oral solution film plus QLM1016 dummy oral solution film administered orally once daily for 6 weeks.

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY